about
Smoldering multiple myeloma.Vaccines versus immunotherapy: overview of approaches in deciding between optionsPomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study.Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitorsDifferential effects of lenalidomide during plasma cell differentiationThe Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependencePomalidomide for multiple myeloma.Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.The safety of pomalidomide for the treatment of multiple myeloma.Pomalidomide in the management of relapsed multiple myeloma.In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review.Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide.The proteasome and proteasome inhibitors in multiple myeloma.'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.Burkholderia multivorans: A rare yet emerging cause of bacterial meningitis.A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma.
P2860
Q28082855-4153CBF8-18BE-4E02-A0BF-829B01B479BEQ28085434-2A291CE3-C8FD-4DC7-AB3C-BB2B85B10535Q30802505-1149059E-BFD5-462F-8612-F0076C4D22CFQ33816582-281BBCC4-125A-4E71-BBCF-B9629B74563CQ35784505-BCDD433E-BBEF-4EB9-8814-032305C2520EQ36700492-97E6689E-7F55-4C37-8DD0-9AA3449491B8Q37317494-BA35705F-764F-4961-AB30-1C02F9262A1EQ37517482-B440D459-415C-4322-A277-FDDDDEB9A655Q37740928-FE01C5DE-15B7-4127-8AB4-19F1559E0FF5Q38255265-948ED889-D40D-427F-A103-8CC24AD7AE96Q38658649-68137F18-A286-467F-A1D2-F13EA7F9FE4EQ38749362-35583C5F-D8BC-456C-BE71-8D96F1D1BD6CQ38855510-0C0D03A6-9559-45EB-97EF-D2444F63AA9CQ39425529-0C5456CD-1B20-44F2-AC0F-4A7D95F1A298Q41966805-5EAC65FF-C48C-4D1E-8942-907214E0731FQ47339695-8396C764-DB00-47C0-A501-ECAD8886C04EQ48205014-66060A2B-DFF3-4650-ACC4-0CFAE2E18DD3Q52331531-8B4742C0-B440-49AF-833A-4ED391C5E561Q54978920-A8E0DF47-273D-4A76-AEA9-9B6228ADE7C8
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Pomalidomide.
@en
type
label
Pomalidomide.
@en
prefLabel
Pomalidomide.
@en
P1433
P1476
Pomalidomide.
@en
P2093
Arleigh R McCurdy
P304
P356
10.1182/BLOOD-2013-05-484782
P407
P577
2013-08-23T00:00:00Z